Five Strategies For Designing Successful Complex Rare Disease Trials

By Martin Roessner, Corporate Vice President, Biostatistics, and Jamie Pierson, Senior Project Leader, Cell and Gene Therapy

Breakthroughs in rare disease medicine start with trial designs that can keep pace with the science. Developing therapies for rare conditions presents distinct challenges for sponsors: small, geographically dispersed patient populations, limited natural history data, and complex or evolving endpoints that require thoughtful scientific and operational planning. These constraints demand innovation—not only in study design but in how evidence is generated, interpreted, and communicated.

Successful rare disease trials increasingly rely on adaptive methodologies that allow teams to modify elements of the study as data emerge, maximizing learning from small cohorts. Creative endpoint selection—including surrogate markers, composite measures, and patient‑centered outcomes—can help capture meaningful signals when traditional measures fall short. Strong, early collaboration with regulatory agencies help ensure alignment on trial expectations, evidence sufficiency, and pathways that balance rigor with feasibility.

By combining innovative design with proactive stakeholder engagement, sponsors can generate high‑quality evidence while accelerating development timelines. This approach enables teams to overcome the inherent challenges of small populations, improve trial efficiency, and bring urgently needed therapies to patients living with rare diseases more quickly and confidently.